Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10.4-HspX

Vaccine

Volumn 29, Issue 51, 2011, Pages 9451-9458

  Niu, Hongxia ^a   Hu, Lina ^b   Li, Qing ^a   Da, Zejiao ^a   Wang, Bingxiang ^b   Tang, Kefeng ^a   Xin, Qi ^a   Yu, Hongjuan ^a   Zhang, Ying ^a,c   Wang, Yong ^d   Ma, Xingming ^a   Zhu, Bingdong ^a  

^a LANZHOU UNIVERSITY   (China)

^b LANZHOU INSTITUTE OF BIOLOGICAL PRODUCTS   (China)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d WUHAN UNIVERSITY   (China)

Author keywords

HspX; Mtb10.4; Multi stage vaccine; Mycobacterium tuberculosis; Subunit vaccine

Indexed keywords

BCG VACCINE; CORD FACTOR; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; HYBRID PROTEIN; IMMUNOLOGICAL ADJUVANT; PROTEIN MTB10.4 HSPX; SUBUNIT VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BACILLUS; CELLULAR IMMUNITY; CHROMATOGRAPHY; CLINICAL ARTICLE; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; T LYMPHOCYTE; TUBERCULOSIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; FEMALE; HUMANS; INTERFERON-GAMMA; MICE; MICE, INBRED C57BL; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, SUBUNIT;

EID: 81955164734     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.10.032     Document Type: Article

References (48)

1. Kumar V., Abbas A.K., Fausto N., Mitchell R.N. Robbins basic pathology 2007, Saunders/Elsevier, Philadelphia.
2. Corbett E.L., Bandason T., Cheung Y.B., Munyati S., Godfrey-Faussett P., Hayes R., et al. Epidemiology of tuberculosis in a high HIV prevalence population provided with enhanced diagnosis of symptomatic disease. PLoS Med 2007, 4:e22.
3. Caminero J.A. Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding. Int J Tuberc Lung Dis 2010, 14:382-390.
4. World Health Organization Global tuberculosis control 2010, Available from: http://www.who.int/tb/publications/global_report/2010/en/index.html.
5. Andersen P. Vaccine strategies against latent tuberculosis infection. Trends Microbiol 2007, 15:7-13.
6. Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organization, 1991. Bull World Health Organ 2001, 79:71-75.
7. Young D., Dye C. The development and impact of tuberculosis vaccines. Cell 2006, 124:683-687.
8. Fine P.E. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995, 346:1339-1345.
9. Fine P.E. BCG vaccination against tuberculosis and leprosy. Br Med Bull 1988, 44:691-703.
10. Horwitz M.A., Harth G., Dillon B.J., Maslesa-Galic S. Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 2000, 97:13853-13858.
11. Grode L., Seiler P., Baumann S., Hess J., Brinkmann V., Nasser Eddine A., et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 2005, 115:2472-2479.
12. Martin C., Williams A., Hernandez-Pando R., Cardona P.J., Gormley E., Bordat Y., et al. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine 2006, 24(24):3408-3419.
13. Sambandamurthy V.K., Derrick S.C., Jalapathy K.V., Chen B., Russell R.G., Morris S.L., et al. Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis. Infect Immun 2005, 73:1196-1203.
14. Verreck F.A., Vervenne R.A., Kondova I., van Kralingen K.W., Remarque E.J., Braskamp G., et al. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS One 2009, 4:e5264.
15. Magalhaes I., Sizemore D.R., Ahmed R.K., Mueller S., Wehlin L., Scanga C., et al. rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector. PLoS One 2008, 3:e3790.
16. Weinrich Olsen A., van Pinxteren L.A., Meng Okkels L., Birk Rasmussen P., Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and ESAT-6. Infect Immun 2001, 69:2773-2778.
17. Dietrich J., Aagaard C., Leah R., Olsen A.W., Stryhn A., Doherty T.M., et al. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol 2005, 174:6332-6339.
18. Skeiky Y.A., Alderson M.R., Ovendale P.J., Guderian J.A., Brandt L., Dillon D.C., et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 2004, 172:7618-7628.
19. Geluk A., Lin M.Y., van Meijgaarden K.E., Leyten E.M., Franken K.L., Ottenhoff T.H., et al. T-cell recognition of the HspX protein of Mycobacterium tuberculosis correlates with latent M. tuberculosis infection but not with M. bovis BCG vaccination. Infect Immun 2007, 75:2914-2921.
20. Skjot R.L., Oettinger T., Rosenkrands I., Ravn P., Brock I., Jacobsen S., et al. Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens. Infect Immun 2000, 68:214-220.
21. Olsen A.W., Williams A., Okkels L.M., Hatch G., Andersen P. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect Immun 2004, 72:6148-6150.
22. Langermans J.A., Doherty T.M., Vervenne R.A., van der Laan T., Lyashchenko K., Greenwald R., et al. Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 2005, 23:2740-2750.
23. Skjot R.L., Brock I., Arend S.M., Munk M.E., Theisen M., Ottenhoff T.H., et al. Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family. Infect Immun 2002, 70:5446-5453.
24. Billeskov R., Grandal M.V., Poulsen C., Christensen J.P., Winther N., Vingsbo-Lundberg C., et al. Difference in TB10.4 T-cell epitope recognition following immunization with recombinant TB10.4, BCG or infection with Mycobacterium tuberculosis. Eur J Immunol 2010, 40:1342-1354.
25. Vekemans J., Ota M.O., Sillah J., Fielding K., Alderson M.R., Skeiky Y.A., et al. Immune responses to mycobacterial antigens in the Gambian population: implications for vaccines and immunodiagnostic test design. Infect Immun 2004, 72:381-388.
26. Saxena A., Srivastava V., Srivastava R., Srivastava B.S. Identification of genes of Mycobacterium tuberculosis upregulated during anaerobic persistence by fluorescence and kanamycin resistance selection. Tuberculosis (Edinb) 2008, 88:518-525.
27. Yuan Y., Crane D.D., Simpaon R.M., Zhu Y., Hickey M.J., Sheramn D.R., et al. The 16-kDa A-crystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages. Microbiology 1998, 95:9578-9583.
28. Demissie A., Leyten E.M., Abebe M., Wassie L., Aseffa A., Abate G., et al. Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Clin Vaccine Immunol 2006, 13:179-186.
29. Nilsson J., Stahl S., Lundeberg J., Uhlen M., Nygren P.A. Affinity fusion strategies for detection, purification, and immobilization of recombinant proteins. Protein Expr Purif 1997, 11:1-16.
30. Shimp R.L., Martin L.B., Zhang Y., Henderson B.S., Duggan P., MacDonald N.J., et al. Production and characterization of clinical grade Escherichia coli derived Plasmodium falciparum 42kDa merozoite surface protein 1 (MSP1(42)) in the absence of an affinity tag. Protein Expr Purif 2006, 50:58-67.
31. Christensen D., Foged C., Rosenkrands I., Nielsen H.M., Andersen P., Agger E.M. Trehalose preserves DDA/TDB liposomes and their adjuvant effect during freeze-drying. Biochim Biophys Acta 2007, 1768:2120-2129.
32. Li Q., Yu H., Zhang Y., Wang B., Jiang W., Da Z., et al. Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice. Scand J Immunol 2011, 73:568-576.
33. Agger E.M., Rosenkrands I., Hansen J., Brahimi K., Vandahl B.S., Aagaard C., et al. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One 2008, 3:e3116.
34. Luo Y., Wang B., Hu L., Yu H., Da Z., Jiang W., et al. Fusion protein Ag85B-MPT64(190-198)-Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against Mycobacterium tuberculosis in mice. Vaccine 2009, 19(27):6179-6185.
35. Oftung F., Borka E., Mustafa A.S. Mycobacterium tuberculosis reactive T cell clones from naturally converted PPD-positive healthy subjects: recognition of the M. tuberculosis 16-kDa antigen. FEMS Immunol Med Microbiol 1998, 20:319-325.
36. Wilkinson R.J., Wilkinson K.A., De Smet K.A., Haslov K., Pasvol G., Singh M., et al. Human T- and B-cell reactivity to the 16kDa alpha-crystallin protein of Mycobacterium tuberculosis. Scand J Immunol 1998, 48:403-409.
37. Wang K.L. National Technic Steering Group Of The Epidemiological Sampling Survey For Tuberculosis. Report on fourth national epidemiological sampling survey of tuberculosis. Chin J Tuberc Respir Dis 2002, 25:3-7. [Chinese].
38. Shi C., Chen L., Chen Z., Zhang Y., Zhou Z., Lu J., et al. Enhanced protection against tuberculosis by vaccination with recombinant BCG over-expressing HspX protein. Vaccine 2010, 28:5237-5244.
39. Aagaard C., Hoang T., Dietrich J., Cardona P.J., Izzo A., Dolganov G., et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 2011, 17:189-194.
40. MacMicking J.D., Taylor G.A., McKinney J.D. Immune control of tuberculosis by IFN-gamma-inducible LRG-47. Science 2003, 302:654-659.
41. Flynn J.L., Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001, 19:93-129.
42. MacMicking J.D., North R.J., LaCourse R., Mudgett J.S., Shah S.K., Nathan C.F. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci USA 1997, 94:5243-5248.
43. Singh S.B., Davis A.S., Taylor G.A., Deretic V. Human IRGM induces autophagy to eliminate intracellular Mycobacteria. Science 2006, 313:1438-1441.
44. Fossiez F., Djossou O., Chomarat P., Flores-Romo L., Ait-Yahia S., Maat C., et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996, 183:2593-2603.
45. Khader S.A., Bell G.K., Pearl J.E., Fountain J.J., Rangel-Moreno J., Cilley G.E., et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007, 8:369-377.
46. Hoft D.F. Tuberculosis vaccine development: goals, immunological design, and evaluation. Lancet 2008, 372:164-175.
47. de Valliere S., Abate G., Blazevic A., Heuertz R.M., Hoft D.F. Enhancement of innate and cell-mediated immunity by antimycobacterial antibodies. Infect Immun 2005, 73:6711-6720.
48. Finkelman F.D., Holmes J., Katona I.M., Urban J.F., Beckmann M.P., Park L.S., et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol 1990, 8:303-333.